Peripheral artery disease affects more than 200 million people worldwide and is driven by the progressive narrowing of arteries outside the heart, most often in the femoropopliteal segment of the leg, where atherosclerosis, thrombosis, and calcification combine to choke off blood supply. In its most severe form, critical limb ischemia, patients suffer rest pain, non-healing wounds, and a high risk of amputation. The standard treatment is endovascular revascularization—typically balloon angioplasty and stenting—but severe calcification stiffens the vessel wall, causing elastic recoil, dissection, and difficulty delivering and expanding devices. Orbital atherectomy was engineered to solve this problem. It uses a diamond-coated crown that orbits eccentrically inside the artery, sanding down calcified plaque while theoretically sparing the vessel from deep injury. The device has been reported to generate microparticles averaging roughly two micrometers in diameter—smaller than red blood cells—suggesting that the debris it produces would be too fine to cause clinically significant blockages downstream.

That assumption has now been directly tested. Researchers at the University of Nebraska Omaha and the University of Nebraska Medical Center obtained ten human femoropopliteal artery segments from tissue donors, all with advanced atherosclerosis and calcification. Nine of the donors were male, with a mean age of 77 years, and the donor cohort reflected the typical risk profile of the disease: all had hypertension, half had diabetes and chronic kidney disease, most had dyslipidemia, and nearly all had smoked. Each artery was mounted in a custom pulsatile flow loop designed to approximate the hemodynamics of the leg artery under resting conditions, complete with a compliance chamber, real-time pressure and flow sensors, and a 100-micrometer filter positioned downstream to capture anything the treatment dislodged.

The experimental protocol mirrored clinical practice. Each vessel underwent baseline imaging and hemodynamic assessment, then treatment with the Diamondback 360 orbital atherectomy system over its dedicated guidewire, with passes at rotational speeds of 60, 90, and 140 thousand revolutions per minute, followed by balloon angioplasty with semi-compliant balloons inflated to nominal pressure. At each stage, micro-computed tomography at voxel resolutions of 50 to 55 micrometers quantified the flow lumen, pressure transducers measured the translesional mean arterial pressure gradient, an ultrasonic flow meter recorded net flow, and the downstream filter was photographed and analyzed with custom image-analysis software to quantify every captured particle.

The headline finding concerns the debris. Orbital atherectomy generated embolic material with a mean captured area of 0.386 square millimeters per particle distribution, and the sizes were alarming: 90 percent of the arteries released fragments of at least 1 millimeter, and 10 percent shed fragments exceeding 5 millimeters—debris capable of obstructing the popliteal or femoral arteries themselves. On average, each specimen released about 87 particles small enough to occlude arterioles, 19 particles in the range of perforator arteries, and roughly 5.5 particles that could block digital arteries, with half to 60 percent of specimens producing emboli in the size range of plantar and tibial vessels. Subsequent balloon angioplasty added smaller debris, averaging 0.143 square millimeters, apparently dislodging plaque that the atherectomy had already loosened. Because embolic protection filters in clinical use may not capture fragments this large, the authors argue the implications for patient safety are considerable.

The study also quantified the benefits that have made the device popular. Flow lumen volume increased significantly and additively across treatment stages, rising by a total of 0.409 milliliters from baseline to after both interventions, with orbital atherectomy contributing 0.180 milliliters and balloon angioplasty adding another 0.229 milliliters. Inner-diameter pulsatility—a measure of how much the lumen itself expands with each heartbeat, and a proxy for luminal compliance—increased from 1.5 percent at baseline to 2.3 percent after the combined treatment, a statistically significant improvement. These results support the core concept behind plaque modification: sanding away calcium does make the channel larger and more distensible, potentially reducing the need for high-pressure ballooning and bailout stenting, a benefit previously reported in trials such as COMPLIANCE 360, which found bailout stenting in just 5.3 percent of atherectomy patients versus 77.8 percent with balloon angioplasty alone.

But the hemodynamic gains were strikingly uneven. The translesional pressure gradient fell by a clinically meaningful margin of more than 10 millimeters of mercury in only 40 percent of the arteries, showed minimal improvement in 50 percent, and actually worsened in 10 percent, in one case because a flow-limiting dissection was created. Net flow improved by at least a quarter in 40 percent of specimens but was unchanged in 30 percent and decreased in the remaining 30 percent, including one artery that lost 41 percent of its flow due to dissection. Dissections were a frequent companion of the treatment, typically occurring at the interface between plaque and vessel wall, and were often exacerbated by the subsequent ballooning. Notably, while the inner lumen became more distensible, the outer diameter pulsatility—measured with both duplex ultrasound and a high-resolution external camera—did not change, suggesting the procedure improves luminal compliance without fundamentally altering the stiffness of the vessel wall itself.

These bench findings dovetail with a growing body of clinical evidence. In the Vascular Study Group of New England registry, orbital atherectomy carried a 4.3 percent embolization rate—77 percent higher than balloon angioplasty and 64 percent higher than stenting—and 68 percent of those embolic events required additional intervention, including open surgery in 11 percent of cases. The LIBERTY 360 registry reported embolization in 7.8 percent of diabetic patients with critical limb ischemia treated with the device, four times the rate seen in non-diabetics. A recent Japanese study of rotational atherectomy with active aspiration found angiographic embolization in more than a third of calcified femoropopliteal procedures and true embolic events in over half. Meanwhile, large analyses of Vascular Quality Initiative and Medicare data have linked atherectomy overall to a 3.7-fold higher risk of major amputation compared with stenting and a 1.5-fold higher risk compared with balloon angioplasty, alongside more major adverse limb events.

The economics add another layer of concern. The Diamondback 360 catheter costs 3,795 dollars in the United States, the average index procedure costs 11,729 dollars, and two-year peripheral artery disease-related costs with atherectomy exceed those of balloon angioplasty or stenting by 6,500 to 8,000 dollars. Medicare outpatient spending on atherectomy ballooned from 86 million dollars in 2011 to 612 million dollars in 2021, a trajectory that has drawn national scrutiny. Against that backdrop, the new study’s authors argue that orbital atherectomy is best reserved for patients with severely calcified lesions in whom plaque modification offers a clear procedural advantage, and should be used cautiously, if at all, in patients at elevated risk of clinically significant distal embolization or when comparable revascularization can be achieved less aggressively. Embolic protection devices, they note, deserve renewed attention given the fragment sizes observed.

The authors are careful to acknowledge the limits of their model. The sample of ten arteries limited statistical power; the specimens were cadaveric and lacked vasoreactivity, healing responses, and thrombosis; the absence of surrounding soft tissue may have altered how the crown interacted with the wall, potentially underestimating debris generation; and the standardized treatment protocol could not capture the operator-dependent variability of real-world practice. Still, the study is the first to systematically combine micro-CT imaging, physiological flow simulation, embolic capture, and pulsatility measurement on the same human arteries across sequential treatment stages, and its central conclusion is difficult to escape: the plaque-modifying benefits of orbital atherectomy are real, but they come bundled with a consistent and substantial shower of embolic debris and vessel wall injury that may explain why the device’s procedural successes have not translated into the superior long-term patency and limb salvage that patients and clinicians hoped for.

Subject of Research: Biomechanical and embolic effects of orbital atherectomy in calcified human femoropopliteal arteries

Article Title: High Embolic Risk with Orbital Atherectomy for Calcified Peripheral Artery Disease

Article References: Gilyazov, R., de Oliveira, B. B., Glushkov, M., Deegan, P., MacTaggart, J., & Kamenskiy, A. (2026). High Embolic Risk with Orbital Atherectomy for Calcified Peripheral Artery Disease. Annals of Biomedical Engineering. https://doi.org/10.1007/s10439-026-04370-9

Image Credits: AI Generated

DOI: 10.1007/s10439-026-04370-9

Keywords: peripheral artery disease, orbital atherectomy, embolization, vascular calcification, femoropopliteal artery, balloon angioplasty, critical limb ischemia, endovascular revascularization, arterial compliance, embolic debris, vessel dissection, biomechanics